Caers J, Vande broek I, De Raeve H, Michaux L, Trullemans F, Schots R, Van Camp B, Vanderkerken K (2008) Multiple myeloma—an update on diagnosis and treatment. Eur J Haematol 81:329–343
Binsfeld M, Fostier K, Muller J, Baron F, Schots R, Beguin Y, Heusschen R, Caers J (2014) Cellular immunotherapy in multiple myeloma: lessons from preclinical models. Biochim Biophys Acta 1846:392–404
Goldstein AL, Low TL, McAdoo M, McClure J, Thurman GB, Rossio J, Lai CY, Chang D, Wang SS, Harvey C, Ramel AH, Meienhofer J (1977) Thymosin alpha 1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A 74:725–729
Sarandeses CS, Covelo G, Diaz-Jullien C, Freire M (2003) Prothymosin alpha is processed to thymosin alpha 1 and thymosin alpha 11 by a lysosomal asparaginyl endopeptidase. J Biol Chem 278:13286–13293
Favalli C, Jezzi T, Mastino A, Rinaldi-Garaci C, Riccardi C, Garaci E (1985) Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol Immunother 20:189–192
Bozza S, Gaziano R, Bonifazi P, Zelante T, Pitzurra L, Montagnoli C, Moretti S, Castronari R, Sinibaldi P, Rasi G, Garaci E, Bistoni F, Romani L (2007) Thymosin alpha 1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo. Int Immunol 19:1261–1270
Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, Pitzurra L, Bellocchio S, Velardi A, Rasi G, Di Francesco P, Garaci E (2004) Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 103:4232–4239
Sztein MB, Serrate SA (1989) Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J Immunopharmacol 11:789–800
Baumann CA, Badamchian M, Goldstein AL (1997) Thymosin alpha 1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+ CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways. Mech Ageing Dev 94:85–101
Knutsen AP, Freeman JJ, Mueller KR, Roodman ST, Bouhasin JD (1999) Thymosin-alpha 1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model. Int J Immunopharmacol 21:15–26
Lao X, Liu M, Chen J, Zheng H (2013) A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1. Plos One 8:e72242
Xue XC, Yan Z, Li WN, Li M, Qin X, Zhang C, Hao Q, Wang ZL, Zhao N, Zhang W, Zhang YQ (2013) Construction, expression, and characterization of thymosin alpha 1 tandem repeats in Escherichia coli. Biomed Res Int 2013:720285
Perruccio K, Bonifazi P, Topini F, Tosti A, Bozza S, Aloisi T, Carotti A, Aversa F, Martelli MF, Romani L, Velardi A (2010) Thymosin alpha 1 to harness immunity to pathogens after haploidentical hematopoietic transplantation. Ann N Y Acad Sci 1194:153–161
Giuliani C, Napolitano G, Mastino A, Di Vincenzo S, D’Agostini C, Grelli S, Bucci I, Singer DS, Kohn LD, Monaco F, Garaci E, Favalli C (2000) Thymosin-alpha 1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol 30:778–786
Bubenik J (2004) MHC class I down-regulation: tumour escape from immune surveillance? (review). Int J Oncol 25:487–491
Moody TW, Leyton J, Zia F, Tuthill C, Badamchian M, Goldstein AL (2000) Thymosin alpha1 is chemopreventive for lung adenoma formation in A/J mice. Cancer Lett 155:121–127
Moody TW, Tuthill C, Badamchian M, Goldstein AL (2002) Thymosin alpha 1 inhibits mammary carcinogenesis in Fisher rats. Peptides 23:1011–1014
Moody TW, Fagarasan M, Zia F, Cesnjaj M, Goldstein AL (1993) Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo. Cancer Res 53:5214–5218
Schulof RS, Lloyd MJ, Cleary PA, Palaszynski SR, Mai DA, Cox JW Jr, Alabaster O, Goldstein AL (1985) A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer. J Biol Response Mod 4:147–158
Sungarian A, Cielo D, Sampath P, Bowling N, Moskal P, Wands JR, de la Monte SM (2009) Potential role of thymosin-alpha 1 adjuvant therapy for glioblastoma. J Oncol 2009:302084
Pica F, Fraschetti M, Matteucci C, Tuthill C, Rasi G (1998) High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anticancer Res 18:3571–3578
Maio M, Mackiewicz A, Testori A, Trefzer U, Ferraresi V, Jassem J, Garbe C, Lesimple T, Guillot B, Gascon P, Gilde K, Camerini R, Cognetti F, Thymosin Melanoma Investigation G (2010) Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol 28:1780–1787
Rasi G, Silecchia G, Sinibaldi-Vallebona P, Spaziani E, Pierimarchi P, Sivilia M, Tremiterra S, Garaci E (1994) Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int J Cancer 57:701–705
Silecchia G, Guarino E, Sinibaldi-Vallebona P, Pierimarchi P, Restuccia A, Spaziani E, Bernard P, Tuthill C, Garaci E, Rasi G (1999) Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha 1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery. Cancer Immunol Immunother 48:172–178
Lauritzsen GF, Bogen B (1993) The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Cell Immunol 148:177–188
Hofgaard PO, Jodal HC, Bommert K, Huard B, Caers J, Carlsen H, Schwarzer R, Schunemann N, Jundt F, Lindeberg MM, Bogen B (2012) A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. Plos One 7:e51892
Garrett IR, Dallas S, Radl J, Mundy GR (1997) A murine model of human myeloma bone disease. Bone 20:515–520
Oyajobi BO, Munoz S, Kakonen R, Williams PJ, Gupta A, Wideman CL, Story B, Grubbs B, Armstrong A, Dougall WC, Garrett IR, Mundy GR (2007) Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther 6:1701–1708
Binsfeld M, Beguin Y, Belle L, Otjacques E, Hannon M, Briquet A, Heusschen R, Drion P, Zilberberg J, Bogen B, Baron F, Caers J (2014) Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. Plos One 9:e113764
Otjacques E, Binsfeld M, Rocks N, Blacher S, Vanderkerken K, Noel A, Beguin Y, Cataldo D, Caers J (2013) Mithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors. Plos One 8:e62818
Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, Watanabe T, Akashi K, Shultz LD, Harada M (2005) Development of functional human blood and immune systems in NOD/SCID/IL2 receptor gamma chain(null) mice. Blood 106:1565–1573
Li M, Feurino LW, Li F, Wang H, Zhai Q, Fisher WE, Chen C, Yao Q (2007) Thymosin alpha 1 stimulates cell proliferation by activating ERK1/2, JNK, and increasing cytokine secretion in human pancreatic cancer cells. Cancer Lett 248:58–67
Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B (2005) Primary antitumor immune response mediated by CD4+ T cells. Immunity 22:371–383
Ding JH, Wang LL, Chen Z, Wang J, Yu ZP, Zhao G, Chen BA (2013) The role of T alpha 1 on the infective patients after hematopoietic stem cell transplantation. Int J Hematol 97:280–283
Wang B, He F, Lin Y, Huang M, Zhou SF (2007) Effect of recombinant human thymosin-alpha 1, an immuno-modulating peptide with 28 amino acids, on the activity of cytochrome P450s. Drug Metab Lett 1:199–204
